EE Impact

Krewel Meuselbach

Germany · Pharma & Healthcare

LeaveRussia detail: Exit Completed

Exited Russia

Krewel Meuselbach GmbH is a German, owner-operated pharmaceutical company known for producing high-quality herbal medicines (phyto-pharmaceuticals) and conventional drugs, manufacturing in Germany (Eitorf & Gehren) for global markets, specializing in liquid/solid forms like syrups and tablets, and offering contract manufacturing. Established from the merger of Krewel Werke (est. 1893) and Meuselbach, they focus on holistic therapy with herbal alternatives and modern pharmaceutical development, serving customers in over 20 countries.

Status last verified 03/08/2026Source checked 31/12/2025Company website ↗LeaveRussia profile ↗

Decision trail

Decision date 25/11/2025 · Reference ↗

Received revenues in Russia in 2022-2024. Revenue decreased in 2024 vs 2023 by more than -10%. 25.11.2025: Dr. Theiss Naturvaren GmbH becomes the new founder of KREVEL MEUSELBACH LLC. KREVEL MEUSELBACH GmbH has been removed from the Unified State Register of Legal Entities.

Local stats (LeaveRussia)

Assets(RF), mln.USD
8
Capital(RF), mln.USD
1
Revenue(RF), mln.USD
13
Staff(RF), 2021
28

Status history since 2022

  1. 03/08/2026 exited · Imported from KSE LeaveRussia

Exposure profile

Full exposure profile is a Professional feature

Energy, transport and commodity exposure, supplier/customer links in the region and sanctioned-party proximity.

Upgrade to Professional
Statuses, logos and narrative notes are compiled from public reporting and the KSE LeaveRussia project. Found an error? See our corrections policy.